GLP-1 medications were approved for diabetes and obesity. But a rapidly expanding body of research — backed in some cases by large clinical trials and, in at least one, an FDA approval — suggests the drug class may have meaningful…
GLP-1s
Researchers at Philadelphia-based Penn Medicine have found women who used GLP-1 medications were about 30% less likely to develop breast cancer than women who did not use the drugs. Here are five notes:
A wave of recent research is expanding what clinicians and health system leaders know about GLP-1 medications — from their place in obesity treatment to emerging benefits in oncology and gastrointestinal care. Here are six recent study findings: 1. Eli…
Eli Lilly’s Mounjaro (tirzepatide) delivered better blood sugar control and weight loss than other GLP-1 medications when added early in Type 2 diabetes treatment, according to a new study published May 26 in Annals of Internal Medicine. The Surpass-Early trial…
CVS Caremark has expanded coverage options for GLP-1 weight management medications, including the return of Zepbound as a preferred formulary option — reversing a decision that drew significant patient pushback. CVS Caremark initially selected Wegovy as the preferred GLP-1 for…
Advertisement
Eli Lilly’s new obesity drug is posting weight loss results that rival — and in some cases exceed — gastric bypass surgery, long considered the only effective treatment for most patients with severe obesity. Lilly announced May 21 that its…
In 2026, the U.S. prescription drug market is predicted to exceed $1 trillion for the first time, and GLP-1 drugs such as Ozempic, Zepbound and Wegovy are the primary drivers of this growth. GLP-1s accounted for 14% of U.S. drug…
Maryland’s Prescription Drug Affordability Board has voted to place an upper payment limit on Ozempic for state and local government health plans, a first for the nation, and a move supporters said could save about $5.8 million annually. The board…
CMS launches its Medicare GLP-1 Bridge July 1, giving eligible Medicare Part D beneficiaries access to weight-loss GLP-1s at a $50 monthly copay through December 2027. For health systems and pharmacy leaders, the launch means new workflow requirements, a likely…
Novo Nordisk said oral Wegovy outperformed Eli Lilly’s orforglipron on weight loss and treatment tolerability in new analyses. The company shared findings from its Orion indirect treatment comparison and Optic patient preference studies, which compared 25-milligram oral semaglutide with 36-milligram…